News
tiakis Biotech AG Announces Appointment of ex-Actelion Executive Christoph Schmidt as New Supervisory Board Member
– Successful track record in the commercialization of biopharmaceutical products as well as strategic advisory in orphan diseases
tiakis Biotech AG, a clinical-stage biopharmaceutical company developing novel therapeutics for life-threatening pulmonary and cardiovascular diseases, today announced that Dr. Christoph Schmidt has been appointed to the Company´s Supervisory Board.
Dr. Schmidt is a global senior executive with nearly three decades of experience in the biotechnology, pharmaceutical, and life sciences industries. During his leadership roles at Actelion and Johnson & Johnson, he launched four global blockbuster products, three of them in the rare disease Pulmonary Arterial Hypertension (PAH). Read more…